Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages.
Murray
Lynne A
LA
Promedior, Inc, Malvern, Pennsylvania, United States of America. MurrayL@MedImmune.com
Rosada
Rogerio
R
Moreira
Ana Paula
AP
Joshi
Amrita
A
Kramer
Michael S
MS
Hesson
David P
DP
Argentieri
Rochelle L
RL
Mathai
Susan
S
Gulati
Mridu
M
Herzog
Erica L
EL
Hogaboam
Cory M
CM
D000368:Aged; D000818:Animals; D001761:Bleomycin / Q000494:pharmacology*; D003094:Collagen / Q000378:metabolism; D005260:Female; D005355:Fibrosis; D006801:Humans; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000473:pathology; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D000683:Serum Amyloid P-Component / Q000096:biosynthesis*
D000683:Serum Amyloid P-Component; D001761:Bleomycin; D003094:Collagen